Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avastin bevacizumab regulatory update

DNA resubmitted an sBLA to expand the label of Avastin plus paclitaxel chemotherapy to include the treatment of chemotherapy-naïve

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE